These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20233509)

  • 1. Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom.
    Lewis G; Peake M; Aultman R; Gyldmark M; Morlotti L; Creeden J; de la Orden M
    J Int Med Res; 2010; 38(1):9-21. PubMed ID: 20233509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysis.
    Cromwell I; van der Hoek K; Melosky B; Peacock S
    J Thorac Oncol; 2011 Dec; 6(12):2097-103. PubMed ID: 22052223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting.
    Nadler E; Forsyth M; Satram-Hoang S; Reyes C
    J Thorac Oncol; 2012 Jan; 7(1):212-8. PubMed ID: 22124474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib for the treatment of relapsed non-small cell lung cancer.
    McLeod C; Bagust A; Boland A; Hockenhull J; Dundar Y; Proudlove C; Davis H; Green J; Macbeth F; Stevenson J; Walley T; Dickson R
    Health Technol Assess; 2009 Jun; 13 Suppl 1():41-7. PubMed ID: 19567213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
    Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
    Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer.
    Carlson JJ; Garrison LP; Ramsey SD; Veenstra DL
    Value Health; 2009; 12(1):20-7. PubMed ID: 18647257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
    Lee VW; Schwander B; Lee VH
    Hong Kong Med J; 2014 Jun; 20(3):178-86. PubMed ID: 24281768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
    Carlson JJ; Wong WB; Veenstra DL; Reyes C
    J Med Econ; 2011; 14(2):159-66. PubMed ID: 21288059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective.
    Doral Stefani S; Giorgio Saggia M; Vicino dos Santos EA
    J Med Econ; 2008; 11(3):383-96. PubMed ID: 19450094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
    Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
    J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
    Garassino MC; Martelli O; Broggini M; Farina G; Veronese S; Rulli E; Bianchi F; Bettini A; Longo F; Moscetti L; Tomirotti M; Marabese M; Ganzinelli M; Lauricella C; Labianca R; Floriani I; Giaccone G; Torri V; Scanni A; Marsoni S;
    Lancet Oncol; 2013 Sep; 14(10):981-8. PubMed ID: 23883922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
    Cromwell I; van der Hoek K; Malfair Taylor SC; Melosky B; Peacock S
    Lung Cancer; 2012 Jun; 76(3):472-7. PubMed ID: 22226627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
    Thongprasert S; Tinmanee S; Permsuwan U
    Asia Pac J Clin Oncol; 2012 Mar; 8(1):53-61. PubMed ID: 22369444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC).
    Carlson JJ; Reyes C; Oestreicher N; Lubeck D; Ramsey SD; Veenstra DL
    Lung Cancer; 2008 Sep; 61(3):405-15. PubMed ID: 18295368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial.
    Hornberger J; Hirsch FR; Li Q; Page RD
    Lung Cancer; 2015 May; 88(2):223-30. PubMed ID: 25804732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer. Rev Port Pneumol 2008; 14(6):803-827.
    Bartminski W
    Rev Port Pneumol; 2009; 15(3):555-9; author reply 560-6. PubMed ID: 19526635
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan.
    Ramsey SD; Clarke L; Kamath TV; Lubeck D
    J Manag Care Pharm; 2006; 12(6):472-8. PubMed ID: 16925455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
    Vergnenegre A; Corre R; Berard H; Paillotin D; Dujon C; Robinet G; Crequit J; Bota S; Thomas P; Chouaid C;
    J Thorac Oncol; 2011 Jan; 6(1):161-8. PubMed ID: 21150465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.